EMBO | EMBL Symposium - Organoids: modelling organ development and disease in 3D

Date
22-25 October, 2025
Time
Location
Heidelberg, Germany

The EMBO | EMBL Symposium: Organoids – Modelling Organ Development and Disease in 3D brings together leading researchers to discuss the latest advances in organoid generation and applications. This event highlights how organoid systems are transforming our understanding of tissue development, disease mechanisms, and regenerative medicine.

The 2025 edition will explore new frontiers in the field, integrating complementary technologies such as multiomics, bioengineering, and engineered embryo models — and placing a stronger focus on cancer-related organoid research.

MaxWell Biosystems is excited to take part with a booth, poster, talk, and workshop. Visit us to learn how our High-Density Microelectrode Array (HD-MEA) technology enables detailed functional readouts from organoids and 3D cultures. Our team will be happy to discuss your samples and applications, and help you identify the best approach for your research.

Join us in Heidelberg to connect, exchange ideas, and explore how electrophysiology can bring new insights into complex organoid systems.

Meet the MxW Team

Dr. Silvia Oldani

Senior Field Application Scientist | MaxWell Biosystems (Switzerland)

Biography

Dr Anastasiia, Tourbier

Field Application Scientist | MaxWell Biosystems (Switzerland)

Biography

Inés, Blanc Giró

Account & Event Coordinator | MaxWell Biosystems (Switzerland)

Biography

MxW Booth

Find us at booth #3130: come meet us in person and explore what’s new!

No items found.

Poster 
Presentations

Dr. Anastasiia Tourbier

Field Application Scientist | MaxWell Biosystems (Switzerland)

Friday October 24, 2025 | 16:30-18:30 | Poster #228

Next-generation electrophysiology for functional characterization of human neural organoids and assembloids

Abstract

Human-induced pluripotent stem cell (hiPSC)-derived three-dimensional neural models, such as organoids and assembloids, have become essential tools for mimicking key aspects of human brain development. These self-organizing in vitro systems significantly contribute to the study of neurodegenerative diseases, including Alzheimer’s and Parkinson’s. Real-time, label-free monitoring of electrical activity is crucial for analyzing the complex behavior of neuronal networks in these models.

High-Density Microelectrode Arrays (HD-MEAs) provide a powerful, non-invasive platform for high-resolution electrical imaging, enabling real-time recordings across a broad spectrum of electrogenic samples, from neural organoids and assembloids to brain and retinal tissue slices. In this study, we used the MaxOne and MaxTwo HD-MEA Systems, each featuring 26,400 electrodes per well, to capture extracellular action potentials from 3D neural models at multiple levels of resolution, ranging from subcellular compartments and single cells to whole networks. Flexible electrode selection capabilities of these platforms contributed to improved data reproducibility and statistical robustness. Key parameters such as firing rates, spike amplitudes, and network burst characteristics were analyzed. To gain deeper insight into subcellular processes, the AxonTracking Assay was employed to map action potential propagation along axonal branches, enabling detailed examination of axonal properties such as conduction velocity, latency, length, and branching patterns.  

The ability of these HD-MEA platforms to selectively target electrodes improves data quality while enhancing reproducibility. Combined with the integrated tools for automated data visualization and metric extraction, the systems presented here offer a robust, user-friendly platform, supporting both acute and long-term electrophysiological studies in disease modelling and drug testing.

Biography

Workshops

Wednesday, October 22, 2025 | 12:00 -13:00
Modeling Alzheimer’s Disease in Cerebral Organoids: From Amyloid β Accumulation to APOE4-Specific Drug Responses

Alzheimer’s disease (AD) is characterized by progressive neurodegeneration, amyloid pathology, and limited treatment options. Conventional models fail to fully capture the complexity of human-specific mechanisms, prompting the development of cerebral organoids derived from induced pluripotent stem cells (iPSCs) as disease-relevant platforms. We thus established AD organoid models capable of recapitulating hallmark features of pathology, including extracellular amyloid β (Aβ) cluster formation and elevated levels of Aβ peptides detectable in culture media. Using organoids carrying familial AD mutations in PSEN1, single-cell RNA sequencing revealed accelerated neuronal differentiation, consistent with previously reported hyperexcitability phenotypes in AD models. We further extended our work by initiating a single-cell sequencing atlas of AD cerebral organoids, enabling detailed characterization of disease-associated transcriptional programs. Importantly, we show that AD pathology can be reproduced across multiple genetic backgrounds, including SORL1 variants. Lastly, beyond modeling, we employed organoids for therapeutic testing and demonstrated that Tramiprosate exerts selective effects on APOE4 organoids, altering lipid metabolism, while leaving APOE3 organoids largely unaffected. Our findings thus highlight cerebral organoids as a robust platform for modeling genetic risk factors, dissecting molecular mechanisms of AD, and evaluating genotype-specific drug responses. This approach bridges the gap between fundamental research and translational applications, advancing our understanding of Alzheimer’s disease at the single-cell level.

Dr. Dáša, Bohačiaková
Masaryk University (Brno, Czech Republic)

Register

Which activities are you attending?

You can unsubscribe from marketing emails at any time. For details, see our Privacy Policy.

Submit
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
MaxWell